GlassScriptPhysician profile
Richard J Lund
NPI 1609969468
$377,523.52
in general payments reported to CMS, 2019-2025
31 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $5,125 · 2021: $57K · 2022: $85K · 2023: $27K · 2024: $66K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $85K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $26K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $9,252 · Consulting Fee: $6,645 · Education: $54.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $84,537.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,850.00 |
| Travel and Lodging | $26,201.26 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,700.00 |
| Food and Beverage | $9,251.99 |
| Consulting Fee | $6,645.17 |
| Education | $54.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $149,349.35 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $58,078.11 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $48,522.06 | 2024-2025 | Tarpeyo |
| Vifor Pharma, INC. | $45,575.94 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $45,514.80 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $19,992.02 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $7,872.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $443.70 | 2019-2024 | Lokelma, Farxiga |
| Bard Peripheral Vascular, INC. | $410.79 | 2023-2025 | Pristine, Covera |
| Amgen INC. | $243.80 | 2021-2025 | Tavneos, Aranesp, Krystexxa |
| Medtronic, INC. | $177.24 | 2025 | Symplicity G3 |
| Scpharmaceuticals INC. | $167.74 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $163.72 | 2023-2024 | |
| Genzyme Corporation | $149.12 | 2024-2025 | |
| Nxstage Medical, INC. | $135.01 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $133.23 | 2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $125.96 | 2024-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $99.99 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $73.99 | 2024-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.21 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $44.71 | 2023-2024 | Benlysta |
| Cormedix INC. | $28.60 | 2024 | Defencath |
| Lilly USA, LLC | $24.00 | 2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $21.57 | 2025 | Yorvipath |
| Novo Nordisk INC | $20.69 | 2025 | Wegovy |
| Azurity Pharmaceuticals, INC. | $18.22 | 2024 | Horizant |
| Outset Medical INC | $17.34 | 2019 | |
| Mozarc Medical US LLC | $17.25 | 2024 | Palindrome |
| Fresenius USA Marketing, INC. | $16.87 | 2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $14.23 | 2025 | |
| Aurinia Pharma U.S., INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.